Weight-loss drugs among breakthrough trials offering ‘hope' for dementia prevention
Dozens of breakthrough drug trials, including one using the main ingredient in weight-loss jabs, offer patients 'hope' for the treatment and prevention of dementia and Alzheimer's disease.
Some 138 treatments are being assessed in clinical trials in 2025 - an 11 per cent rise on the year before - according to new research published on Tuesday.
Experts have said that 2025 could be a 'landmark year' in breakthrough medicines as four drugs that could prevent the disease, not just treat it, have progressed to large clinical trials.
Some trials include drugs currently used to treat other conditions. One such trial is assessing whether semaglutide, the main ingredient for the weight loss and diabetes drugs Ozempic and Wegovy, can slow the progression of dementia.
An estimated 982,000 people are living with dementia in the UK, and this is projected to rise to 1.4 million in 2040, according to the Alzheimer's Society.
Dr Emma Mead, chief scientific officer of the Oxford Drug Discovery Institute, added: 'Today we are at a tipping point in dementia research as we understand more and more about the diseases that drive dementia.
'This gives us opportunities to slow and ultimately stop this devastating condition, and today's announcement demonstrates that researchers are able to translate these understandings towards potential new treatments.'
Dr Richard Oakley, associate director of research at Alzheimer's Society, said: '2025 is shaping up to be a landmark year for Alzheimer's disease drug development.
'With more trials underway than ever before and more drugs entering the pipeline, there is hope on the horizon for the nearly one million people living with dementia in the UK.'
A report from the University of Nevada in the US and published in the journal Alzheimer's and Dementia: Translational Research and Clinical Interventions, said a 'robust' range of drugs was being trialled in 2025 and a 'notable increase' showed 'momentum toward identifying new therapies for the treatment of alzheimer's disease'.
Experts said that drugs, such as such as lecanemab and donanemab, that target amyloid protein build-up in the brain - a key characteristic of both diseases - are 'only one part of the overall strategy' as they expressed excitement over the variety of new drugs being tested.
James Rowe, professor of cognitive neurology at the University of Cambridge and consultant neurologist, said: 'One of the most exciting things of this report is the number of large-scale late-stage trials on prevention. And the aspiration to prevent, not just treat, is starting to be seen in the figures we see in these charts today.'
He added: 'The ones that are in trial at the moment are really… bringing forward an effective treatment to earlier stage.'
For instance, people with a genetic risk of Alzheimer's could receive some drugs earlier to see if they protect them against developing the disease.
Dr Sheona Scales, director of research at Alzheimer's Research UK, said that, as well as more drugs coming through the pipeline, the treatment targets are 'more diverse' and 'looking at all stages of the disease'.
She added: 'What this paper is showing us is that the pipeline of drug development is growing, it's diversifying and accelerating.'
Meanwhile, academics said lecanemab and donanemab, which can be used for treating mild cognitive impairment in Alzheimer's patients, are an 'important first step' in the battle against the disease.
The treatments were initially approved for UK use by regulators but then deemed not cost-effective for NHS use.
The National Institute for Health and Care Excellence (NICE) is taking more evidence on donanemab and lecanemab and is expected to announce its decision in the summer.
Dr Scales added: 'Lecanemab and donanemab have represented a huge leap forward in our understanding and ability to be able to treat Alzheimer's disease.
'What they've done is they've proved that we're able to modify the course of Alzheimer's disease, and what that has done is opened up the door to future treatments that we hope are more effective, easier to deliver and and able to deliver for our patients.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
26 minutes ago
- BBC News
World Environment Day 2025: What is plastic pollution and why is it a problem?
It's World Environment Day on 5 June, a day organised by the United Nations where campaigners aim to inspire people to take action to protect our planet from climate change and raise awareness of issues around the year's theme is all about plastic pollution and what we can do to tackle it.A recent study by an ocean charity found that the amount of plastic rubbish found on beaches in the UK had increased by nearly 10%.The Marine Conservation Society (MCS) said that their volunteers had picked up three quarters of a million pieces of litter across beaches in the UK in what is plastic pollution and why is it a problem? Keep reading to find you or your school doing anything for World Environment Day? Let us know in the comments below. What is plastic? Plastic is in lots of things we use from clothing to crisp packets, and bottles to things from plastic is popular because there are many different types - and it can be made in to all sorts of shapes, colours and can be coloured or clear, thick or thin, strong or you look around your home or school, you'll find most things have plastic in them, including your pencil case, games consoles, and even are man-made and can be produced from natural materials like coal and oil. What is plastic pollution and why is it a problem? Plastic pollution is when plastic waste ends up in the environment, and it can damage our oceans, rivers, lakes and main problem with plastic is that most of it isn't biodegradable. That means it doesn't break down in the environment like paper or food, so instead it can hang around for hundreds of year, 400 million tonnes of plastic is produced and 40% of that is single-use - plastic we'll only use once before it's of single-use plastic are carrier bags, drinks bottles and crisp packets. Millions of tonnes of plastic enters the world's oceans each year and most of that escapes from bits of plastic, called microplastics, have also been found in things like the food we eat and soil in the ground and even in the air we can be blown into the sea from ships and beaches, or carried there by river. Some also gets flushed down the issue is that not all plastic can be might be because of the way it is made up or because it is too expensive or difficult to do. What's already being done about plastic pollution? In March 2022, nearly 200 UN countries agreed to start negotiations on an international plan on how to deal with plastic leaders are trying to agree the plastic pollution treaty - setting rules on how plastic is made, used and thrown away - and how the treaty is paid year's World Environment Day comes exactly two months before countries meet in Switzerland to continue negotiating a global agreement to end plastic UN Environment Programme (Unep) aims to bringing countries together to try to work on issues that affect the to the programme, plastic pollution is one of the defining environmental challenges of our time.
The Independent
31 minutes ago
- The Independent
Charity asks government to fund retired police dogs' costly care
The Thin Blue Paw Foundation is appealing to the Government to provide pensions for retired police dogs to alleviate the financial burden on handlers and owners. Since August 2020, the foundation has distributed £380,000 in grants for veterinary expenses, addressing health issues stemming from the dogs' demanding work. Foundation chairman Kieran Stanbridge argues the Home Office has a moral obligation to support these dogs in retirement, given their service and sacrifice. The foundation has launched a petition to push the Government for a ring-fenced budget to support owners of retired police dogs. There are about 1,700 serving police dogs in the UK and about 100 retire each year.
Reuters
40 minutes ago
- Reuters
London stocks mixed as markets brace for ECB rate decision
June 5 (Reuters) - Britain's benchmark FTSE 100 index edged higher on Thursday, while mid-caps retreated as investors awaited the European Central Bank's interest rate decision. As of 0948 GMT, the blue-chip index FTSE 100 (.FTSE), opens new tab was up 0.2% while the domestically-focussed FTSE 250 (.FTMC), opens new tab fell 0.2%. Shares of Wizz Air (WIZZ.L), opens new tab plunged 25.9%, weighing heavily on the midcap index, after the budget carrier reported an around 62% slide in annual operating profit, citing capacity constraints due to grounded planes. The slump rippled through the travel sector (.FTNMX405010), opens new tab with other airline stocks like easyJet (EZJ.L), opens new tab and ICAG (ICAG.L), opens new tab declining over 1% each. On the flip side, Dr Martens (DOCS.L), opens new tab jumped 23.2% and was the top gainer on the midcap index after the bootmaker announced plans to reduce discounting in key markets, including the U.S., and forecast a return to profit growth in this financial year. The ECB rate decision is scheduled for later in the day, with market watchers almost certain the central bank will cut rates by 25 basis points. Instead, focus will be on bank President Christine Lagarde's signals about future policy decisions. Friday's U.S. non-farm payrolls data will also command attention as evidence mounts of economic damage from President Donald Trump's tariff policies, following weak jobs and services data for the month of May. U.S. Defense Secretary Pete Hegseth has said that a defence spending commitment of 5% of GDP across the NATO alliance will happen, ahead of the bloc's defence ministers' meeting. A gauge of the UK's defence stocks (.FTNMX502010), opens new tab was down 0.4% in the day. Back home, British construction firms reduced staff numbers last month at the fastest pace in nearly five years, reflecting higher wage costs and reduced demand, a survey showed on Thursday. Data by the Bank of England revealed 70% of businesses surveyed in May expect no impact on sales, prices or investment plans from U.S. tariffs. Among other movers, Mitie Group (MTO.L), opens new tab slid 11% after the outsourcing firm suspended 125 million pounds ($169.5 mln) share buyback programme. ($1 = 0.7374 pounds)
